Biogen drops 2% to $298.20 after PTC"s spinal muscular atrophy data
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Biogen down 3% to $296 after PTC"s spinal muscular atrophy data
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Technical Take: Biogen falls sharply after PTC"s spinal muscular atrophy data
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Biogen presents new Spinraza data in Spinal Muscular Atrophy
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Biogen quarterly sales rise 9 percent
Biogen Inc reported a 9 percent rise in quarterly revenue on Tuesday, helped by demand for its spinal muscular atrophy drug Spinraza......»»
Genentech presents new data for risdiplam in Spinal Muscular Atrophy
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Scholar Rock"s Apitegromab gets FDA fast track in Spinal Muscular Atrophy
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Novartis"s $90 million Swiss factory to help solve cell therapy bottleneck
Swiss drugmaker Novartis's new $90 million cell and gene therapy factory in northern Switzerland is on track to begin commercial production of treatments, including Kymriah for cancer and Zolgensma for spinal muscular atrophy, in 2020......»»
FDA Investigates Data Manipulation Issue With Newly Approved Novartis Drug Zolgensma
Novartis AG (NYSE: NVS)'s Zolgensma, the first gene therapy approved for pediatric patients with spinal muscular dystrophy Type 1, has caught the FDA's attention due to a disclo read more.....»»
The FDA approves gene therapy that is the most expensive drug in the world
Drug firm Novartis’s Zolgensma, a $2.1 million one-time gene therapy, treats infants with spinal muscular atrophy......»»
The FDA approves a gene therapy that is the most expensive drug in the world
The gene therapy Zolgensma, priced at $2.1 million, treats infants with spinal muscular atrophy......»»
The costliest drug on the planet will treat infants with rare disease. The market fight focused on cost and safety is just getting started.
Infants with spinal muscular atrophy may soon have two treatment options......»»
The costliest drug on the planet will treat infants with rare disease.
Infants with spinal muscular atrophy may soon have two treatment options......»»
The costliest drug on the planet will treat infants with rare disease.
Infants with spinal muscular atrophy may soon have two treatment options......»»
Why Novartis Is Paying $8.7 Billion for a Gene Therapy Developer You’ve Never Heard Of
AveXis's main drug treats spinal muscular atrophy (SMA), a degenerative genetic condition. On Monday, Novartis CEO Vasant Narasimhan announced the company would buy the Illin.....»»
BMO: Scholar Rock Holds Opportunity In Multibillion-Dollar Spinal Muscular Atrophy Market
As Scholar Rock Holding Corp (NASDAQ: SRRK)’s IPO quiet period expired Monday, four analysts came out with bullish recommendations on the stock. Latest Ratings for SRRK Dat.....»»
PTC Therapeutics reports results of risdiplam in spinal muscular atrophy
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Biogen announces data from SPINRAZA clinical development program
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Biogen presents data from portfolio of multiple sclerosis therapies
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
: FibroGen stock drops as biotech clarifies data classification in study data
FibroGen Inc. FGEN shares fell in .....»»
Biogen"s stock is up 5% after Lilly reports positive data from an Alzheimer"s study
Shares of Biogen Inc. gained 5.6% in trading on Monday after another drugmaker shared positive clinical data about an experimental Alzheimer's disease treatment that is similar to a Biogen therapy under review by the Food and Drug A.....»»